Institutional members access full text with Ovid®

Share this article on:

Apolipoprotein A-I mimetics and high-density lipoprotein function

Gordon, Scott M.; Davidson, William S.

Current Opinion in Endocrinology, Diabetes and Obesity: April 2012 - Volume 19 - Issue 2 - p 109–114
doi: 10.1097/MED.0b013e32835056d4
LIPIDS: Edited by Annabelle Rodriguez

Purpose of review To review recently published advances in the development of apolipoprotein A-I (apoA-I) mimetic peptides as a potential treatment for cardiovascular diseases.

Recent findings Various apoA-I mimetic peptides are currently in development and these display potent cardioprotective features that can rival or even surpass those of full length apoA-I and high-density lipoproteins (HDLs). These features include the ability to efflux cholesterol from various cell types as well as anti-inflammatory and antioxidative properties. Recent work has been aimed at identifying the structural features of these peptides that are responsible for these various functions and also for determining the operational mechanisms. There is also interesting new data suggesting that the intestine may be playing an important role in the action of these peptides.

Summary In the last year, there have been many important advances in the relatively new field of apoA-I mimetic therapy. These findings support a strong potential for their development as treatment for not only cardiovascular disease but other disease states involving chronic inflammation and oxidation as well.

University of Cincinnati Metabolic Diseases Institute, Cincinnati, Ohio, USA

Correspondence to W.S. Davidson, PhD, Department of Pathology, University of Cincinnati Metabolic Diseases Institute, 2180 East Galbraith Road, Cincinnati, OH 45237, USA. Tel: +1 513 558 3707; e-mail:

© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins